Mean log10 viral load for each experimental group from the average of 5 values obtained during Weeks 21 to 25, corresponding to 8 to 12 weeks following the interruption of HAART [clinicaltrials_resource:8f54cbe36595dfef034d9feb4b157dbb]

Mean log10 viral load for each experimental group from the average of 5 values obtained during Weeks 21 to 25, corresponding to 8 to 12 weeks following the interruption of HAART [clinicaltrials_resource:8f54cbe36595dfef034d9feb4b157dbb]

Click here for more information on aldesleukin
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:8f54cbe36595dfef034d9feb4b157dbb
Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV [clinicaltrials:NCT00056797]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Mean log10 viral load for each experimental group from the average of 5 values obtained during Weeks 21 to 25, corresponding to 8 to 12 weeks following the interruption of HAART [clinicaltrials_resource:8f54cbe36595dfef034d9feb4b157dbb]

Click here for more information on aldesleukin
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:8f54cbe36595dfef034d9feb4b157dbb
Bio2RDF identifier
8f54cbe36595dfef034d9feb4b157dbb
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:8f54cbe36595dfef034d9feb4b157dbb
measure [clinicaltrials_vocabulary:measure]
Mean log10 viral load for each ...... wing the interruption of HAART
description
Click here for more information on aldesleukin
identifier
clinicaltrials_resource:8f54cbe36595dfef034d9feb4b157dbb
title
Mean log10 viral load for each ...... wing the interruption of HAART
@en
inDataset
type
label
Mean log10 viral load for each ...... 4cbe36595dfef034d9feb4b157dbb]
@en